8-K: Sight Sciences Reports Mixed Q4 Results but Projects Return to Growth in 2024

Sight Sciences announced its Q4 and full year 2023 financial results, showing a decrease in Q4 revenue but an overall increase for the year, and provided 2024 financial guidance.

Summary

• Sight Sciences reported a 9% decrease in fourth-quarter revenue to $18.8 million compared to the same period last year, while full-year 2023 revenue increased by 14% to $81.1 million.
• The company experienced a reduction in operating expenses in Q4 2023, decreasing by 20% to $27.1 million, and a 27% reduction in non-GAAP adjusted operating expenses to $22.3 million.
• Cash used in operations was reduced to $46.9 million for the full year 2023, an improvement from $75.7 million in 2022, and further reduced to $6.4 million in Q4 2023.
• Sight Sciences secured a new senior secured credit facility for up to $65 million, with an initial $35 million tranche funded in January 2024.
• The company maintained Medicare patient access for its OMNI and SION surgical systems after a review and withdrawal of local coverage determinations.
• Clinical trials for OMNI and TearCare technologies showed positive results, with OMNI demonstrating sustained intraocular pressure and medication reductions, and TearCare showing improvements in dry eye symptoms.
• For 2024, Sight Sciences projects revenue between $81 million and $85 million, with an expected return to double-digit growth in the second half of the year, and adjusted operating expenses between $107 million and $110 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the full-year revenue growth, cost reductions, and positive clinical trial results, but tempered by the Q4 revenue decline and the risks associated with the 2024 guidance.

Positives

• Full year revenue increased by 14% year-over-year.
• Operating expenses and cash burn were significantly reduced in Q4 2023 and for the full year.
• The company secured a new credit facility, strengthening its balance sheet.
• Medicare coverage for key products was maintained.
• Clinical trials demonstrated the effectiveness of both OMNI and TearCare technologies.
• Gross margin improved to 85% for the full year 2023.
• The company anticipates a return to double-digit revenue growth in the second half of 2024.

Negatives

• Fourth-quarter revenue decreased by 9% compared to the same period in the prior year.
• Dry Eye revenue decreased by 11% in Q4 2023.
• The company experienced lower utilization and new account additions in Q4 2023 due to uncertainty from withdrawn LCDs.
• Dry Eye gross margin declined to 53% in Q4 2023 due to inventory reserve charges.

Risks

• The company's 2024 financial guidance is subject to risks and uncertainties, including changes in reimbursement, clinical trial outcomes, legal proceedings, economic conditions, and supply chain issues.
• The company faces potential challenges in achieving its projected revenue growth due to market conditions and competition.
• Pending litigation could result in higher legal expenses, impacting adjusted operating expenses.
• Changes in Medicare coverage decisions and reimbursement rates could affect the company's revenue.

Future Outlook

Sight Sciences projects full year 2024 revenue to range from approximately $81.0 million to $85.0 million, representing a range of 0% to 5% growth compared to 2023, with double-digit revenue growth expected in the second half of 2024. The company expects full year 2024 adjusted operating expenses of approximately $107.0 million to $110.0 million.

Management Comments

• Paul Badawi, co-founder and CEO, stated that the company is proud of its achievements in 2023 and its team's resilience during a challenging LCD process.
• Mr. Badawi believes the company's restructuring and cost reductions will lead to predictable long-term results.
• Management expects to expand clinical data, make progress on reimbursement for TearCare, and return to double-digit revenue growth in the second half of 2024.

Industry Context

This announcement comes as the medical device industry continues to focus on innovative solutions for eye care, particularly in glaucoma and dry eye disease. The company's focus on minimally invasive procedures and clinical data aligns with current trends in the industry.

Comparison to Industry Standards

• Sight Sciences' 14% revenue growth for 2023 is a solid performance in the medical device sector, although the Q4 revenue decline is a concern.
• Companies like Glaukos and Ivantis, which also focus on MIGS devices, have seen varying growth rates, making direct comparisons challenging without more detailed market data.
• The 85% gross margin is strong, indicating efficient manufacturing and pricing strategies, and is comparable to other established medical device companies.
• The reduction in operating expenses and cash burn is a positive sign, as many medical device companies struggle with profitability in their early stages.
• The clinical trial results for OMNI and TearCare are promising and could give Sight Sciences a competitive edge over companies using traditional treatments like eye drops (e.g. Restasis by Allergan).

Stakeholder Impact

• Shareholders may be concerned about the Q4 revenue decline but encouraged by the cost reductions and future growth prospects.
• Employees may be affected by the restructuring and cost-reduction measures.
• Customers may benefit from the continued innovation and clinical validation of the company's products.
• Suppliers may be impacted by changes in production volumes and supply chain management.
• Creditors may be reassured by the company's improved financial discipline and new credit facility.

Next Steps

• The company plans to expand clinical data for its glaucoma and dry eye technologies.
• Sight Sciences aims to achieve meaningful reimbursement for TearCare.
• The company expects to return to double-digit revenue growth in the second half of 2024.
• The company plans to publish 12-month crossover clinical data for TearCare in the first half of 2024.
• The company expects to conclude the 2-year follow up for the SAHARA trial by the end of 2024.

Key Dates

Keywords

Sight Sciences, OMNI Surgical System, TearCare, Glaucoma, Dry Eye Disease, MIGS, Financial Results, Revenue, Operating Expenses, Clinical Trials, Medicare, Reimbursement